Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Baxter
Johnson and Johnson
Dow
Harvard Business School

Last Updated: December 7, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,815,835


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,815,835 protect, and when does it expire?

Patent 9,815,835 protects XOFLUZA and is included in two NDAs.

This patent has thirty-eight patent family members in seventeen countries.

Summary for Patent: 9,815,835
Title:Substituted polycyclic carbamolypyridone derivative
Abstract: This invention provides compounds having antiviral activities especially inhibiting activity for influenza virus, more preferably provides substituted 3-hydroxy-4-pyridone derivatives having cap-dependent endonuclease inhibitory activity.
Inventor(s): Akiyama; Toshiyuki (Osaka, JP), Takaya; Kenji (Osaka, JP), Kawai; Makoto (Osaka, JP), Taoda; Yoshiyuki (Osaka, JP), Mikamiyama; Minako (Osaka, JP), Morimoto; Kenji (Osaka, JP), Tomita; Kenji (Osaka, JP), Mikamiyama; Hidenori (Osaka, JP), Suzuki; Naoyuki (Osaka, JP)
Assignee: SHIONOGI & CO., LTD. (Osaka, JP)
Application Number:15/252,791
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 9,815,835

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Genentech Inc XOFLUZA baloxavir marboxil FOR SUSPENSION;ORAL 214410-001 Nov 23, 2020 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Genentech Inc XOFLUZA baloxavir marboxil TABLET;ORAL 210854-001 Oct 24, 2018 RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Genentech Inc XOFLUZA baloxavir marboxil TABLET;ORAL 210854-002 Oct 24, 2018 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Genentech Inc XOFLUZA baloxavir marboxil TABLET;ORAL 210854-003 Mar 18, 2021 RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,815,835

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2009-142166Jun 15, 2009

International Family Members for US Patent 9,815,835

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 102482219 ⤷  Try it Free
China 102803260 ⤷  Try it Free
China 104151234 ⤷  Try it Free
China 104230795 ⤷  Try it Free
China 105037259 ⤷  Try it Free
Denmark 2444400 ⤷  Try it Free
European Patent Office 2412708 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Colorcon
Boehringer Ingelheim
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.